THE-HEALTH-BANK
17.8.2020 11:32:05 CEST | Business Wire | Press release
Salman Arif, the CEO of The Health Bank (THB) Global , announced today that the company is partnering with Nanotronics Health, LLC, to distribute nHaleTM , a non-invasive ventilator. It will be distributed in the Middle East, North Africa and South Asia (MENASA) region. To support non-invasive respiratory therapy in the region, The Health Bank will also train medical professionals to operate the device.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200817005113/en/
“In pursuit of finding a solution for managing COVID-19 symptoms through non-invasive methods, we have partnered with Nanotronics Health, LLC, for the sale and distribution of the nHaleTM . This partnership makes nHaleTM accessible in the Middle East, North Africa, and South Asia (MENASA) region, benefiting patients and health care providers with an affordable, high-quality solution,” said Zarmina Jafar, Head of Strategy at THB Global.
Nanotronics Health, LLC, obtained Emergency Use Authorization (EUA) from the U.S. Food & Drug Administration (FDA) for nHaleTM for use in traditional healthcare facilities, spaces converted for the care of large numbers of COVID-19 patients, and in at-home settings with a doctor’s prescription. This authorization includes the optional use of supplemental oxygen in tandem with nHale™ when a qualified medical professional prescribes it.
Non-invasive ventilation is critical for COVID-19 patient care in the hospital and beyond. To meet this need, Nanotronics Health, LLC, leveraged Nanotronics’ deep in-house expertise, incorporating advanced AI, Intelligent Factory Control (IFC) and sophisticated engineering to conceive, design and manufacture nHaleTM in under 90 days.
“We developed nHaleTM to meet the urgent need for non-invasive respiratory options for patients suffering from COVID-19,” said Julie Orlando, President of Nanotronics Health, LLC. “We designed for quality, comfort and ease of use, making nHaleTM available at a fraction of the cost of other non-invasive ventilators.”
Nanotronics Health, LLC, developed and designed nHale™ to assist spontaneously breathing adults suffering from COVID-19 disease. It is intended for use in non-life-threatening situations, such as a patient in need of breathing assistance but not in need of invasive ventilatory support based on standard medical protocols.
About The Heath Bank
The Health Bank (THB) is a tech-enabled global health management company that offers individuals, families, and corporations a variety of virtual hospital services to support and manage their health and wellness. With a strong focus on prevention and wellness, we empower our members to be proactive about attaining and maintaining a healthy lifestyle, while preventing illness and disease, through our precision medicine and telemonitoring programs.
Our expertise in personalized healthcare delivery offers members and their loved ones peace of mind when facing any chronic or acute healthcare challenge, no matter how complex.
About Nanotronics Health, LLC
Nanotronics Health, LLC, is a subsidiary of and powered by Nanotronics. The company uses Intelligent Factory Control (IFC) to build and scale medical devices that are affordable, accessible and well-designed. Our first product, nHale™, a non-invasive ventilator, was conceived, built, and obtained Emergency Use Authorization by the FDA within 90 days to treat patients suffering from COVID-19. After obtaining Emergency Use Authorization, Nanotronics Health, LLC, immediately began producing and shipping devices.
About nHaleTM
nHale™ is a bi-level positive air pressure device to support respiratory therapy of spontaneously breathing adults weighing over 30kg suffering from COVID-19 disease. It is a non-invasive ventilator designed to be used in non-life-threatening situations, for spontaneously breathing patients, such as a patient in need of breathing assistance but not in need of invasive ventilatory support based on standard medical protocols.
The machine is for use in traditional healthcare facilities (e.g., hospitals, assisted living facilities, nursing homes) as well as spaces converted for the care of large numbers of COVID-19 patients (e.g., convention centers, university dormitories, motels, etc.). nHale™ is also intended for use in home settings with a doctor’s prescription.
Supplemental oxygen may be used with the nHale™ device to increase the oxygen concentration of the airflow being delivered to the patient only when prescribed and trained by a qualified medical professional. The warnings must be observed when using supplemental oxygen with the nHale™ device.
Nanotronics Health LLC, a subsidiary of Nanotronics, applied Nanotronics’ deep in-house expertise, incorporating advanced AI, Intelligent Factory Control (IFC), and sophisticated engineering to build a machine that is easily manufactured at scale and at a reduced cost to increase accessibility for all Americans. nHale™ is designed for comfort and ease-of-use with the simplicity of one button.
nHale™ has been authorized by FDA under an Emergency Use Authorization [EUA]; nHale™ is authorized only for the duration of the declaration that circumstances exist justifying the authorization of the emergency use of the device; nHale™ has not been FDA cleared or approved.
nHale™ is a trademark of Nanotronics in the U.S. which can be found at nanotronics.co/nhale.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200817005113/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
KiddeFenwal Launches New Website and Information Hub8.7.2026 18:00:00 CEST | Press release
Enhanced digital platform reflects KiddeFenwal’s legacy, stature and growth trajectory in the fire suppression and safety controls industry KiddeFenwal, the global leader in the fire suppression and safety controls industry, today unveiled a revitalized website, designed to serve as a comprehensive information hub for fire industry practitioners and customers alike. The modernized platform includes features created specifically with the company’s global partners, OEMs and distributors in mind, including: Accelerated asset navigation, pointing users to critical safety documentation, design parameters and product specifications; Seamless solution mapping, helping users quickly locate fire suppression configurations by industry, from data centers to BESS applications to commercial kitchens; and Enhanced resource access, including streamlined pathways to connect with the company’s elite distributor network across 120 countries. It also provides information about the company’s three brands,
Dryad Networks Reaches XPRIZE Wildfire Finals Milestone, Demonstrating Autonomous Detection and Suppression of Wildfires in Alaska8.7.2026 17:00:00 CEST | Press release
Dryad Networks, the leader in ultra-early wildfire detection technology, today announced a major achievement in the finals of the Autonomous Wildfire Response track of XPRIZE Wildfire, a four-year, $11 million global competition accelerating new solutions to end destructive wildfires. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260707802818/en/ The Silvaguard Suppression Drone can deliver a 100 liter liquid suppressant to autonomously suppress small wildfires detected by Silvanet Competing against just two other finalists selected from an original field of nearly 300 teams worldwide, Dryad successfully demonstrated the integrated capabilities of its Silvanet wildfire detection network and Silvaguard autonomous firefighting drone system during final testing in remote Alaska. The XPRIZE Wildfire finals challenged teams to autonomously detect and suppress a wildfire without any human intervention across a vast 1,000 square k
Rigaku Opens "Rigaku Solutions Center Osaka" to Strengthen Global Semiconductor Metrology Service Capabilities8.7.2026 17:00:00 CEST | Press release
- Centralizing and Expanding Practical Training to Strengthen Global Service Capabilities - Rigaku Corporation, a global solution partner in X-ray analytical systems and a group company of Rigaku Holdings Corporation (headquarters: Akishima, Tokyo; CEO: Jun Kawakami; “Rigaku”), has opened the Rigaku Solutions Center Osaka (RSC-Osaka) at its Osaka Plant. The new facility centralizes and expands practical training for field service engineers supporting semiconductor metrology systems, strengthening Rigaku's global service capabilities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260708402770/en/ Photo: Hands-on training using the TXRF-V310 at RSC-Osaka As semiconductor manufacturing processes continue to advance toward finer geometries, higher layer counts, and more complex three-dimensional structures, semiconductor metrology systems require ever greater precision and operational stability. X-ray analytical technologies pl
Cardiac Dimensions® Announces Three Major Publications Demonstrating Long-Term Durability, Real-World Performance, and Broad Patient Benefit of the Carillon Mitral Contour System®8.7.2026 16:05:00 CEST | Press release
New data highlight multi-center 5-year durability, 10-year survival, and the largest single-center experience across both HFrEF and HFpEF patients with functional mitral regurgitation Cardiac Dimensions, a leader in transcatheter therapies for heart failure, today announced the publication of three major manuscripts that together form the most comprehensive evidence base ever assembled for transcatheter indirect mitral annuloplasty. These publications span a five-year multi-center commercial registry, the largest single-center experience across both preserved and reduced ejection fraction, and long-term survival results through ten years. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260707656796/en/ Carillon Mitral Contour System® The Carillon Mitral Contour System is the only commercially available indirect mitral annuloplasty device, designed to treat a broad and expanding population of patients living with functional mi
First Randomized Controlled Trial Shows Promise of a Ketogenic Diet in Psychotic Disorders8.7.2026 15:00:00 CEST | Press release
Trial reports correlations between ketone levels and cognitive and psychiatric symptoms in individuals with schizophrenia-spectrum and bipolar-1 disorders Published today in Schizophrenia Bulletin, a first-of-its-kind randomized controlled trial (RCT) from researchers at the University of California, San Francisco (UCSF), and funded in part by the National Institute of Mental Health (NIMH), adds to growing literature on the potential benefit of a ketogenic diet for treating psychotic disorders. The study, which enrolled participants with schizophrenia-spectrum or bipolar-1 disorders, demonstrated rapid metabolic improvements with a ketogenic diet compared to diet-as-usual during an initial one-month RCT open-label phase. Furthermore, those who continued with the optional four-month single-arm ketogenic diet extension saw meaningful gains across metabolic, psychiatric, and cognitive measures. This press release features multimedia. View the full release here: https://www.businesswire.co
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom